

United States Patent and Trademark Office



UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
10/719,257	11/21/2003	Veeraiah Bodepudi	21320-US1	2800	
22829	7590 06/21/2006		EXAM	EXAMINER	
ROCHE MOLECULAR SYSTEMS INC PATENT LAW DEPARTMENT 1145 ATLANTIC AVENUE ART UNIT			RILEY,	RILEY, JEZIA	
			ART UNIT	PAPER NUMBER	
ALAMEDA,			1637		
			DATE MAILED: 06/21/2006	6	

Please find below and/or attached an Office communication concerning this application or proceeding.

	Application No.	Applicant(s)		
	10/719,257	BODEPUDI ET AL	. .	
Office Action Summary	Examiner	Art Unit	·	
	Jezia Riley	1637		
The MAILING DATE of this communication appeared for Reply	ppears on the cover sheet	with the correspondence ad	dress	
A SHORTENED STATUTORY PERIOD FOR REP WHICHEVER IS LONGER, FROM THE MAILING (In Extensions of time may be available under the provisions of 37 CFR 1 after SIX (6) MONTHS from the mailing date of this communication. If NO period for reply is specified above, the maximum statutory perior. Failure to reply within the set or extended period for reply will, by statut Any reply received by the Office later than three months after the mail earned patent term adjustment. See 37 CFR 1.704(b).	DATE OF THIS COMMUN 1.136(a). In no event, however, may a d will apply and will expire SIX (6) MO ate, cause the application to become	IICATION. a reply be timely filed DNTHS from the mailing date of this of ABANDONED (35 U.S.C. § 133).	,	
Status				
1) Responsive to communication(s) filed on				
	is action is non-final.	•		
Since this application is in condition for allowance except for formal matters, prosecution as to the merits is				
closed in accordance with the practice under	Ex parte Quayle, 1935 C.	D. 11, 453 O.G. 213.		
Disposition of Claims				
4)⊠ Claim(s) <u>1-78</u> is/are pending in the applicatio	on.			
4a) Of the above claim(s) is/are withdr				
5) Claim(s) is/are allowed.			•	
6) Claim(s) is/are rejected.				
7) Claim(s) is/are objected to.		•		
8) Claim(s) 1-78 are subject to restriction and/o	r election requirement.			
Application Papers				
9) The specification is objected to by the Examir	ner.			
10) The drawing(s) filed on is/are: a) ac		by the Examiner.		
Applicant may not request that any objection to th	• •	•		
Replacement drawing sheet(s) including the corre	ection is required if the drawin	g(s) is objected to. See 37 CF	FR 1.121(d).	
11)☐ The oath or declaration is objected to by the I	Examiner. Note the attache	ed Office Action or form PT	O-152.	
Priority under 35 U.S.C. § 119				
12) Acknowledgment is made of a claim for foreig a) All b) Some * c) None of:	gn priority under 35 U.S.C.	§ 119(a)-(d) or (f).		
 Certified copies of the priority document 	nts have been received.			
2. Certified copies of the priority docume	nts have been received in	Application No		
Copies of the certified copies of the pri	iority documents have bee	n received in this National	Stage	
application from the International Bure	, ,,,			
* See the attached detailed Office action for a lis	st of the certified copies no	ot received.		
AM-ab-contact				
Attachment(s) 1) Notice of References Cited (PTO-892)	4) T taken dan	Summany (DTO 442)		
2) Notice of Draftsperson's Patent Drawing Review (PTO-948)	Paper No	y Summary (PTO-413) o(s)/Mail Date		
 Information Disclosure Statement(s) (PTO-1449 or PTO/SB/0 Paper No(s)/Mail Date 	8) 5) Notice of 6) Other: _	Informal Patent Application (PTC	D-152)	

U.S. Patent and Trademark Office PTOL-326 (Rev. 7-05)

Art Unit: 1637

DETAILED ACTION

Election/Restrictions

Restriction to one of the following inventions is required under 35 U.S.C. 121:

- 1. Claims 1-34, 48-68, drawn to a compound, classified in class 536, subclass 4.1.
- II. Claims 35-47, 79, 80, drawn to an oligonucleotide comprising a label, classified in class 536, subclass 26.6.
- III. Claims 69-74, drawn to a method for detecting the presence or absence of a target nucleic acid, classified in class 435, subclass 6.
- IV. Claim 75, drawn to a method for detecting ribonuclease activity, classified in class 435, subclass 183.
- V. Claim 76, drawn to a method for detecting ribonuclease activity, classified in class 435, subclass 183.
- VI. Claim 77, drawn to a method of detecting endonuclease activity, classified in class 435, subclass 183.
- VII. Claim 78, drawn to a method of making a labeled polynucleotide, classified in class 536, subclass 26.6.

The inventions are distinct, each from the other because of the following reasons:

Art Unit: 1637

Inventions I-II and III-VII are related as product and process of use. The inventions can be shown to be distinct if either or both of the following can be shown: (1) the process for using the product as claimed can be practiced with another materially different product or (2) the product as claimed can be used in a materially different process of using that product. See MPEP § 806.05(h). In the instant case invention I can be used for the method III, IV, V, VI, or VII. Invention II can be used for PCR assay.

Inventions of group I and Group II are related as product and product of a process of use of the products of Group I. The inventions can be shown to be distinct if either or both of the following can be shown: (1) the process for using the product as claimed can be practiced with another materially different product or (2) the product as claimed can be used in a materially different process of using that product (M.P.E.P. § 806.05(h)). In the instant case the compound of Group I can be used in a materially different process of using that product as contrasted with the use of polymerization of these monomers into the oligomer products of Group II. The materially different process of use is in methods of inhibition as substrate analogs or alternatively as in-vivo enzymatic inhibitors of which many mononucleotides are well known.

Because these inventions are independent or distinct for the reasons given above and the inventions require a different field of search (see MPEP § 808.02), restriction for examination purposes as indicated is proper.

Art Unit: 1637

This application contains claims directed to the following patentably distinct species: for the base moiety. The species are independent or distinct because they have different chemical structures.

Applicant is required under 35 U.S.C. 121 to elect a single disclosed species for prosecution on the merits to which the claims shall be restricted if no generic claim is finally held to be allowable. Currently, 1-80 are generic.

Applicant is advised that a reply to this requirement must include an identification of the species that is elected consonant with this requirement, and a listing of all claims readable thereon, including any claims subsequently added. An argument that a claim is allowable or that all claims are generic is considered nonresponsive unless accompanied by an election.

Upon the allowance of a generic claim, applicant will be entitled to consideration of claims to additional species which depend from or otherwise require all the limitations of an allowable generic claim as provided by 37 CFR 1.141. If claims are added after the election, applicant must indicate which are readable upon the elected species.

MPEP § 809.02(a).

Applicant is advised that the reply to this requirement to be complete must include (i) an election of a species or invention to be examined even though the requirement be traversed (37 CFR 1.143) and (ii) identification of the claims encompassing the elected invention.

Art Unit: 1637

The election of an invention or species may be made with or without traverse. To reserve a right to petition, the election must be made with traverse. If the reply does not distinctly and specifically point out supposed errors in the restriction requirement, the election shall be treated as an election without traverse.

Should applicant traverse on the ground that the inventions or species are not patentably distinct, applicant should submit evidence or identify such evidence now of record showing the inventions or species to be obvious variants or clearly admit on the record that this is the case. In either instance, if the examiner finds one of the inventions unpatentable over the prior art, the evidence or admission may be used in a rejection under 35 U.S.C.103(a) of the other invention.

Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Jezia Riley whose telephone number is 571-272-0786. The examiner can normally be reached on 9:30AM - 5:00PM.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Gary Benzion can be reached on 571-272-0782. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Art Unit: 1637

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

Tuesday, June 20, 2006

JEZIA RILEY
PRIMARY EXAMINER

Page 6